Scitaris helps biopharma clients find better in-licensing opportunities with PhD-led, AI-enhanced portfolio strategy

Scitaris-AI, combined with PhD-driven process rigour, enables continuous, real-time analysis of the entire option space.

Scitaris has elevated its business development (BD) consulting offering with Scitaris-AI, a validated biopharma-specific AI agent for high-stakes strategic decision-making. The agent integrates Scitaris’ data and proven consulting frameworks to overcome what have, until now, been key blockers to deploying AI that delivers reproducible, decision-quality output for BD teams. With the tool, Scitaris can now deliver deeper, broader, continuous option space analysis, independent of language barriers, to further reduce the risk of missed opportunities in asset search and evaluation.

Owing to capacity constraints, most biopharma BD teams can interrogate only a subset of available in-licensing opportunities, which means the best options can be missed. Language barriers also leave opportunities in high-growth markets like China out of reach. While companies have looked to large language models (LLMs) for a solution, off-the-shelf models show 64–77% error rates when assessing in-licensing options, making them unusable for BD decisions.

Scitaris-AI, however, delivers 89–95% accuracy and 83–94% reproducibility in in-licensing opportunity evaluation. Using the same proprietary data, structured protocols, and decision criteria that Scitaris’ PhD-level consultants use, Scitaris-AI enables real-time, continuous evaluation of the full option space. By integrating information sources across key markets, including China, Scitaris-AI also eliminates language barriers, which can be a significant source of missed opportunities.

The new AI-enabled analysis workflow rests on three foundations:

Beyond in-licensing opportunity assessment, Scitaris-AI is also being deployed across other BD consulting engagements, including for competitive intelligence gathering.